Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) — Strategic Asset Allocation Index
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has a Strategic Asset Allocation Index of 58.5% as of September 2023. Strategic assets (PP&E of CN¥402.17 Million plus long-term investments of CN¥-) total CN¥402.17 Million, measured against net assets of CN¥687.58 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 300534 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Strategic Asset Allocation Index (2012–2021)
This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's Strategic Asset Allocation Index has evolved across 10 annual periods from 2012 to 2021. As of September 2023, the index stands at 58.5%, representing strategic assets of CN¥402.17 Million against net assets of CN¥687.58 Million CNY. See Gansu Longshenrongfa Pharmaceutical Indu financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2012–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2012 to 2021, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Gansu Longshenrongfa Pharmaceutical Indu market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 41.6% | CN¥305.21 Million | CN¥305.21 Million | CN¥- | CN¥732.84 Million | ▼ -2.6 pp |
| 2020 | 44.2% | CN¥326.76 Million | CN¥326.76 Million | CN¥- | CN¥739.13 Million | ▲ +1.8 pp |
| 2019 | 42.4% | CN¥312.98 Million | CN¥312.98 Million | CN¥- | CN¥738.88 Million | ▼ -8.2 pp |
| 2018 | 50.6% | CN¥364.58 Million | CN¥310.38 Million | CN¥54.20 Million | CN¥720.83 Million | ▼ -10.8 pp |
| 2017 | 61.3% | CN¥436.90 Million | CN¥382.70 Million | CN¥54.20 Million | CN¥712.19 Million | ▲ +4.0 pp |
| 2016 | 57.4% | CN¥403.87 Million | CN¥349.67 Million | CN¥54.20 Million | CN¥703.74 Million | ▼ -30.7 pp |
| 2015 | 88.1% | CN¥357.21 Million | CN¥355.21 Million | CN¥2.00 Million | CN¥405.57 Million | ▲ +46.7 pp |
| 2014 | 41.4% | CN¥150.25 Million | CN¥150.25 Million | CN¥- | CN¥363.10 Million | ▲ +14.4 pp |
| 2013 | 27.0% | CN¥86.10 Million | CN¥86.10 Million | CN¥- | CN¥318.92 Million | ▲ +9.5 pp |
| 2012 | 17.5% | CN¥30.08 Million | CN¥30.08 Million | CN¥- | CN¥171.46 Million | — |